Javascript must be enabled to continue!
Transcriptional Repression of Telomerase RNA Gene Expression by c-Jun-NH2-Kinase and Sp1/Sp3
View through CrossRef
Abstract
Telomerase is essential for immortalization of most human cancer cells. Expression of the core telomerase RNA (hTR) and reverse transcriptase (hTERT) subunits is mainly regulated by transcription. However, hTR transcriptional regulation remains poorly understood. We previously showed that the core hTR promoter is activated by Sp1 and is repressed by Sp3. Here, we show that the mitogen-activated protein kinase kinase kinase 1 (MEKK1)/c-Jun-NH2-kinase (JNK) pathway represses hTR expression by a mechanism that involves Sp1 and Sp3. Promoter activity was induced by the JNK inhibitor SP600125 and was repressed by activated MEKK1. Repression by MEKK1 was blocked by SP600125 or enhanced by coexpression of wild-type but not phosphoacceptor mutated JNK. SP600125 treatment also increased levels of endogenous hTR. Mutations in the hTR promoter Sp1/Sp3 binding sites attenuated SP600125-mediated promoter induction, whereas coexpression of MEKK1 with Sp3 enhanced hTR promoter repression. Chromatin immunoprecipitation showed that levels of immunoreactive Sp1 associated with the hTR promoter were low in comparison with Sp3 in control cells but increased after JNK inhibition with a reciprocal decrease in Sp3 levels. No corresponding changes in Sp1/Sp3 protein levels were detected. Thus, JNK represses hTR promoter activity and expression, apparently by enhancing repression through Sp3. (Cancer Res 2006; 66(3): 1363-70)
American Association for Cancer Research (AACR)
Title: Transcriptional Repression of Telomerase RNA Gene Expression by c-Jun-NH2-Kinase and Sp1/Sp3
Description:
Abstract
Telomerase is essential for immortalization of most human cancer cells.
Expression of the core telomerase RNA (hTR) and reverse transcriptase (hTERT) subunits is mainly regulated by transcription.
However, hTR transcriptional regulation remains poorly understood.
We previously showed that the core hTR promoter is activated by Sp1 and is repressed by Sp3.
Here, we show that the mitogen-activated protein kinase kinase kinase 1 (MEKK1)/c-Jun-NH2-kinase (JNK) pathway represses hTR expression by a mechanism that involves Sp1 and Sp3.
Promoter activity was induced by the JNK inhibitor SP600125 and was repressed by activated MEKK1.
Repression by MEKK1 was blocked by SP600125 or enhanced by coexpression of wild-type but not phosphoacceptor mutated JNK.
SP600125 treatment also increased levels of endogenous hTR.
Mutations in the hTR promoter Sp1/Sp3 binding sites attenuated SP600125-mediated promoter induction, whereas coexpression of MEKK1 with Sp3 enhanced hTR promoter repression.
Chromatin immunoprecipitation showed that levels of immunoreactive Sp1 associated with the hTR promoter were low in comparison with Sp3 in control cells but increased after JNK inhibition with a reciprocal decrease in Sp3 levels.
No corresponding changes in Sp1/Sp3 protein levels were detected.
Thus, JNK represses hTR promoter activity and expression, apparently by enhancing repression through Sp3.
(Cancer Res 2006; 66(3): 1363-70).
Related Results
Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker
Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker
Object. Telomerase activity is responsible for cell immortality. To examine the role of telomerase in the carcinogenesis of human glioblastomas multiforme (GBMs), the authors studi...
Expression of Telomerase Catalytic Component, Telomerase Reverse Transcriptase, in Human Gastric Carcinomas
Expression of Telomerase Catalytic Component, Telomerase Reverse Transcriptase, in Human Gastric Carcinomas
Telomerase activity is believed to be crucial for cellular immortality, which is considered to participate in the development of a majority of human cancers. Human telomerase rever...
Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Abstract
Introduction
Variant calling based on DNA samples has been the gold standard of clinical testing since the advent of Sanger sequencing. The u...
Pan-cancer analysis of Sp1 with a focus on immunological roles in gastric cancer
Pan-cancer analysis of Sp1 with a focus on immunological roles in gastric cancer
Abstract
Background
Sp1, a transcription factor, plays a pivotal role in tumorigenesis across diverse cancers. However, its comprehensive pan-cancer analyses and immunolog...
Short Telomeres, Telomerase Reverse Transcriptase Gene Amplification, and Increased Telomerase Activity in the Blood of Familial Papillary Thyroid Cancer Patients
Short Telomeres, Telomerase Reverse Transcriptase Gene Amplification, and Increased Telomerase Activity in the Blood of Familial Papillary Thyroid Cancer Patients
Background: Differentiated papillary thyroid cancer is mostly sporadic, but the recurrence of the familial form has been reported. Short or dysfunctional telomeres have been associ...
Mediator kinase submodule-dependent regulation of cardiac transcription
Mediator kinase submodule-dependent regulation of cardiac transcription
<p>Pathological cardiac remodeling results from myocardial stresses including pressure and volume overload, neurohumoral activation, myocardial infarction, and hypothyroidism...
Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLC
Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLC
ABSTRACTCurrently, DNA and RNA are used separately to capture different types of gene mutations. DNA is commonly used for the detection of SNVs, indels and CNVs; RNA is used for an...
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
Background
Cancer cells can employ telomerase or the alternative lengthening of telomeres (ALT) pathway for telomere maintenance. Cancer cells that use the ALT pathway exhibit dist...

